One-year Results in 2 Given Gene Therapy at Low Dose Showing Promise, Axovant Reports

One-year Results in 2 Given Gene Therapy at Low Dose Showing Promise, Axovant Reports
Two Parkinson’s patients treated with AXO-Lenti-PD, an investigative gene therapy, in an ongoing clinical trial continue to show improvement 12 months later, Axovant, the therapy’s developer, said in a release. These findings at one year after treatment are important because this timepoint allows for a better assessment of therapy durability, and a more assured differentiation between placebo effects and therapeutic response, ... read more
Source: Parkinson’s News TodayPublished on 2020-01-14By Forest Ray